KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) EBITDA (2017 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed EBITDA for 16 consecutive years, with -$44.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 127.64% year-over-year to -$44.6 million, compared with a TTM value of $255.3 million through Dec 2025, down 48.61%, and an annual FY2025 reading of $409.5 million, down 15.43% over the prior year.
  • EBITDA was -$44.6 million for Q4 2025 at Biomarin Pharmaceutical, down from -$20.1 million in the prior quarter.
  • Across five years, EBITDA topped out at $176.8 million in Q2 2025 and bottomed at -$65.9 million in Q4 2021.
  • Average EBITDA over 5 years is $52.5 million, with a median of $45.5 million recorded in 2022.
  • The sharpest move saw EBITDA skyrocketed 1060.04% in 2023, then crashed 127.64% in 2025.
  • Year by year, EBITDA stood at -$65.9 million in 2021, then soared by 80.13% to -$13.1 million in 2022, then surged by 420.11% to $41.9 million in 2023, then skyrocketed by 285.26% to $161.4 million in 2024, then tumbled by 127.64% to -$44.6 million in 2025.
  • Business Quant data shows EBITDA for BMRN at -$44.6 million in Q4 2025, -$20.1 million in Q3 2025, and $176.8 million in Q2 2025.